I'm only speculating here, but part of the share price drop could be attributed to what is going to be an environment where money will not be so easy to raise.
I suspect a growth business that going out to raise cash now vs 6 months is going to find it very difficult.
Personally, I don't think the business needs that much cash, looks like it is choosing to go down a path where it may need cash if sales growth does not continue to do well. Personally, I think it would have made a big difference if it had done a rights offer to raise say $20m which would have been just a couple of percent of its market cap, I would sure it would be well supported with some investors, and analysts would be much less concerned about the cash position.
David Williams however, being an experienced investment banker himself would probably know a lot more about this than me, and seems very confident that they can continue to drive the sales growth needed to justify the increase in head count and R&D and/or confident they can raise cash while not diluting shareholders too much. He is a big investor in the company having consistently bought a lot of stock on market, so you can be confident he will be trying to look after himself (and us) as an investor as well.
- Forums
- ASX - By Stock
- PNV
- Ann: 1H22 Results Webcast details
Ann: 1H22 Results Webcast details, page-15
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PNV (ASX) to my watchlist
(20min delay)
|
|||||
Last
$2.28 |
Change
-0.025(1.09%) |
Mkt cap ! $1.553B |
Open | High | Low | Value | Volume |
$2.33 | $2.34 | $2.24 | $1.518M | 666.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
40 | 22929 | $2.27 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$2.28 | 32661 | 25 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
40 | 22929 | 2.270 |
24 | 39405 | 2.260 |
13 | 31809 | 2.250 |
15 | 61446 | 2.240 |
11 | 130013 | 2.230 |
Price($) | Vol. | No. |
---|---|---|
2.280 | 32661 | 25 |
2.290 | 49999 | 17 |
2.300 | 63099 | 21 |
2.310 | 119892 | 11 |
2.320 | 17720 | 6 |
Last trade - 15.06pm 15/07/2024 (20 minute delay) ? |
Featured News
PNV (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online